Medical treatment of metastatic melanoma Journal Article
| Authors: | Houghton, A. N.; Meyers, M. L.; Chapman, P. B. |
| Article Title: | Medical treatment of metastatic melanoma |
| Abstract: | The role of combination chemotherapy in the treatment of metastatic melanoma is still a matter of controversy because of the lack of prospective trials directly demonstrating increased response rates and improved survival compared with DTIC alone. Nevertheless, several three-drug regimens have reported response rates between 30%, and 50% in single-institution studies. The duration of response medians of these regimens ranges between 6 and 9 months. However, the survival medians of 6 to 11 months are not substantially better than those of DTIC alone. However, survival at 1 and 2 years following initiation of therapy may more clearly demonstrate an impact of therapies for metastatic melanoma. |
| Keywords: | cancer survival; hydroxyurea; clinical trial; neutropenia; review; cisplatin; cancer combination chemotherapy; alpha interferon; paclitaxel; drug megadose; antineoplastic agent; carboplatin; dacarbazine; interleukin 2; melanoma; phase 2 clinical trial; thrombocytopenia; melphalan; vincristine; carmustine; lomustine; vinblastine; docetaxel; gastrointestinal toxicity; cytokine; bleomycin; vindesine; phase 1 clinical trial; amifostine; intravenous drug administration; fotemustine; autologous bone marrow transplantation; nitrosourea derivative; piritrexim; melatonin; semustine; injection pain; human; priority journal |
| Journal Title: | Surgical Clinics of North America |
| Volume: | 76 |
| Issue: | 6 |
| ISSN: | 0039-6109 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1996-12-01 |
| Start Page: | 1343 |
| End Page: | 1354 |
| Language: | English |
| DOI: | 10.1016/s0039-6109(05)70519-3 |
| PUBMED: | 8977555 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 22 November 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work